REGENXBIO, UPenn settle patent suit with Sarepta over ELEVIDYS
Sarepta will pay REGENXBIO $39.0 million and both sides drop patent litigation tied to ELEVIDYS manufacturing.
SEC filing
Latest
6 stories
Wednesday, September 23
Wednesday, September 16
Gossamer Bio adds Greg Ciongoli to board and audit committee
The seralutinib developer named the Adiumentum Capital founder as a Class III director effective September 16, 2026.
SEC filing
Tuesday, August 25
REGENXBIO adds Greg Ciongoli to board, two directors depart
The gene therapy company named an investment executive to its board while two longtime independent directors retired, effective August 25, 2026.
SEC filing
Monday, August 24
FDA places clinical hold on REGENXBIO's RGX-121 for Hunter Syndrome
REGENXBIO said it does not expect to resubmit the RGX-121 BLA in the near term after asymptomatic spine MRI findings turned up in five trial participants.
SEC filing
Thursday, August 6
Regenxbio reports Q2 2026 results, cites Duchenne trial win and new AbbVie funds
The company raised over $200 million in July, including a $100 million AbbVie milestone, and reaffirmed 2026-2027 timelines for RGX-202, sura-vec and RGX-121.
SEC filing
Monday, July 20
REGENXBIO closes $100 million offering after underwriters exercise full overallotment
The gene therapy company finalized its stock and warrant sale on July 20, 2026, with net proceeds expected near $107.8 million after the underwriters' option was exercised in full.
SEC filing (3)